Showing results (1-10 of 312) with videos related to
Sort By:
Pageof 32
Nature Reviews. Clinical Oncology|February 8, 2017
Precision medicine needs randomized clinical trialsEverardo D Saad, Xavier Paoletti, Tomasz Burzykowski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2019
Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLCJacek Rutkowski, Everardo D Saad, Tomasz Burzykowski, et al.The Oncologist|April 5, 2022
Surrogacy Beyond Prognosis: The Importance of "Trial-Level" SurrogacyMarc Buyse, Everardo D Saad, Tomasz Burzykowski, et al.Journal of the National Cancer Institute|June 23, 2018
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?Everardo D Saad, John R Zalcberg, Julien Péron, et al.BMC Medical Research Methodology|October 5, 2022
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustrationCorinne Jamoul, Laurence Collette, Elisabeth Coart, et al.Cancers|September 28, 2023
Trial Design for Cancer Immunotherapy: A Methodological ToolkitEverardo D Saad, Elisabeth Coart, Vaiva Deltuvaite-Thomas, et al.Statistics in Medicine|October 23, 2023
Minimization in randomized clinical trialsElisabeth Coart, Perrine Bamps, Emmanuel Quinaux, et al.Pharmaceutical Statistics|November 4, 2006
Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validationTomasz Burzykowski, Marc BuyseActa Oncologica (Stockholm, Sweden)|September 15, 2012
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspectsEverardo D Saad, Marc BuyseCurrent Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc BuysePageof 32